Abstracts tagged "Response Criteria"

Abstract Number: 1516 • ACR Convergence 2020
The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership
Philip Carlucci¹, Kristina Deonaraine¹, Andrea Fava², Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…
Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Corinne Miceli-Richard¹, Denis Poddubnyy², Atul Deodhar³, Weibin Bao⁴, Craig Parman⁵, Brian Porter⁶ and Effie Pournara⁵, ¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharmaceuticals Corporation, East Hannover, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Augusta Ortolan¹, Victoria Navarro-Compán², Alexandre Sepriano³, Robert Landewé⁴, Désirée van der Heijde⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center, Padova, Italy, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Leiden University Medical Center, Portela Loures, Portugal, ⁴Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…